Cathie Wood
TXG icon

Cathie Wood’s 10x Genomics TXG Stock Holding History

Cathie Wood’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$384M Sell
10,003,057
-1,714,260
-15% -$44.9M 2.49% 9
2026
Q1 		$249M Sell
11,717,317
-950,052
-7% -$19M 1.93% 16
2025
Q4 		$207M Buy
12,667,369
+779,973
+7% +$11.8M 1.37% 22
2025
Q3 		$139M Sell
11,887,396
-2,004,707
-14% -$26.1M 0.83% 35
2025
Q2 		$161M Buy
13,892,103
+1,046,390
+8% +$9.54M 1.18% 23
2025
Q1 		$112M Buy
12,845,713
+901,656
+8% +$11.4M 1.12% 27
2024
Q4 		$172M Buy
11,944,057
+1,193,712
+11% +$18.8M 1.43% 21
2024
Q3 		$243M Buy
10,750,345
+1,436,582
+15% +$29.7M 2.22% 12
2024
Q2 		$181M Buy
9,313,763
+3,029,951
+48% +$79.3M 1.61% 21
2024
Q1 		$236M Buy
6,283,812
+2,242,525
+55% +$98.5M 1.63% 19
2023
Q4 		$226M Buy
4,041,287
+1,047,827
+35% +$45.6M 1.34% 22
2023
Q3 		$123M Sell
2,993,460
-120,089
-4% -$6.25M 0.94% 25
2023
Q2 		$174M Sell
3,113,549
-1,041,774
-25% -$56.4M 1.15% 23
2023
Q1 		$232M Sell
4,155,323
-161,244
-4% -$7.53M 1.59% 20
2022
Q4 		$157M Sell
4,316,567
-260,247
-6% -$8.51M 1.36% 23
2022
Q3 		$130M Buy
4,576,814
+973,528
+27% +$37.1M 0.91% 26
2022
Q2 		$184M Buy
3,603,286
+211,948
+6% +$11M 1.09% 24
2022
Q1 		$258M Buy
3,391,338
+730,472
+27% +$63.9M 1.08% 25
2021
Q4 		$396M Sell
2,660,866
-441,085
-14% -$67.6M 1.2% 25
2021
Q3 		$452M Sell
3,101,951
-1,198,086
-28% -$206M 1.08% 25
2021
Q2 		$842M Buy
4,300,037
+795,916
+23% +$144M 1.57% 16
2021
Q1 		$634M Buy
3,504,121
+2,970,625
+557% +$513M 1.26% 21
2020
Q4 		$75.5M Buy
533,496
+302,399
+131% +$43.9M 0.2% 83
2020
Q3 		$28.8M Sell
231,097
-105,456
-31% -$11.1M 0.17% 69
2020
Q2 		$30.1M Buy
+336,553
New +$26.2M 0.32% 49

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cathie Wood's TXG Position: Q2 2026 in Review

Cathie Wood reduced its 10x Genomics (TXG) stake by 15% in Q2 2026, selling an estimated $44.9M and leaving 10,003,057 shares worth $384M. The position accounts for 2.49% of the portfolio, ranked #9.

Cathie Wood first reported a position in TXG in Q2 2020 and has held it in 25 quarters since. The position peaked at $842M in Q2 2021. 389 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Cathie Wood held 10,003,057 shares of 10x Genomics worth $384M as of Q2 2026.
  • Cathie Wood sold 1,714,260 10x Genomics shares in Q2 2026, an estimated $44.9M.
  • 10x Genomics made up 2.49% of Cathie Wood's portfolio in Q2 2026, its #9 holding.
  • Cathie Wood first reported a position in 10x Genomics in Q2 2020 and has held it in 25 quarters since.
  • Cathie Wood's 10x Genomics position peaked at $842M in Q2 2021.
  • 389 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on ARK Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.